- Home
- ECBK vs QTRX Comparison
ECBK vs QTRX Comparison
Compare ECBK & QTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ECBK | QTRX |
|---|---|---|
| Founded | 1919 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 144.3M | 160.0M |
| IPO Year | 2022 | 2017 |
Fundamental Metrics
Financial Performance| Metric | ECBK | QTRX |
|---|---|---|
| Price | $18.18 | $3.30 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 10.1K | ★ 877.3K |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 95.83 | N/A |
| EPS | ★ 0.94 | N/A |
| Revenue | $598,000.00 | ★ $37,632,000.00 |
| Revenue This Year | N/A | $25.49 |
| Revenue Next Year | N/A | $10.04 |
| P/E Ratio | $19.23 | ★ N/A |
| Revenue Growth | 3.64 | ★ 64.52 |
| 52 Week Low | $14.83 | $2.95 |
| 52 Week High | $20.05 | $8.77 |
Technical Indicators
Market Signals| Indicator | ECBK | QTRX |
|---|---|---|
| Relative Strength Index (RSI) | 56.60 | 42.30 |
| Support Level | $17.80 | N/A |
| Resistance Level | $18.70 | $3.81 |
| Average True Range (ATR) | 0.28 | 0.25 |
| MACD | -0.06 | 0.07 |
| Stochastic Oscillator | 46.24 | 45.10 |
Price Performance
Historical ComparisonAbout ECBK ECB Bancorp Inc.
ECB Bancorp Inc operates as a bank holding company of Everett Co-operative Bank. The firm through its subsidiary engages in business consisting of taking deposits from the general public and investing those deposits, together with funds generated from operations, in one- to four-family residential real estate loans, commercial real estate, and multifamily real estate loans, construction and land loans and home equity lines of credit.
About QTRX Quanterix Corporation
Quanterix Corp is a life sciences company accelerating biomarker breakthroughs from discovery to diagnostics using ultra-sensitive translational research and spatial biology instruments, consumables, and services. The company sells proprietary instruments and related consumables to research laboratories, contract research organizations (CROs), academic institutions, and bio-pharmaceutical companies, and provides contract research services and clinical laboratory testing services, including four Laboratory Developed Tests (LDTs), through its Accelerator Laboratory. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, and SP-X Imaging and Analysis System. Geographically, it operates in North America, EMEA, and the Asia Pacific.